Lonza GroupXSWX:LONN +2.56%82 EBITDA Margin % is 22.17% as of Dec. 2025, which is 16% below its 10-year median of 26.55. GuruFocus rates XSWX:LONN with a GF Score™ of 82/100 and a GF Value™ of CHF592.67 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Lonza Group ranks better than 71.57% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Lonza Group's EBITDA for the
six
months ended in Dec. 2025 was CHF655 Mil. Lonza Group's Revenue for the
six
months ended in Dec. 2025 was CHF2,955 Mil. Therefore, Lonza Group's EBITDA margin for the quarter that ended in Dec. 2025 was 22.17%.
Lonza Group (XSWX:LONN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Lonza Group EBITDA Margin % Related Terms
Lonza Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Lonza Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:LONN vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Lonza Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lonza Group EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Lonza Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lonza Group (XSWX:LONN) has a EBITDA Margin % of 22.17% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lonza Group and its competitors. This is 16% below median its historical median of 26.55. Over the past decade, Lonza Group's EBITDA Margin % has ranged from 18.27 to 33.86. According to the industry distribution chart, Lonza Group ranks #58 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 28.4%.
Is Lonza Group's EBITDA Margin % too high?
Lonza Group's current EBITDA Margin % of 22.17% is 16% below median its 10-year median of 26.55. Over the past 10 years, this metric has ranged from a low of 18.27 to a high of 33.86. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Lonza Group's value of 22.17% is 326.3% above this industry median. Based on the distribution chart, Lonza Group ranks #58 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Lonza Group has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lonza Group's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lonza Group ranks #58 out of 204 companies for EBITDA Margin %. This puts Lonza Group in the upper half of its industry. The industry median EBITDA Margin % is 5.20. Lonza Group's value of 22.17% is 326.3% above this benchmark. Historically, Lonza Group's own EBITDA Margin % has ranged from 18.27 to 33.86 over the past decade. While the company's 10-year median is 26.55 vs. the industry median of 5.20, Lonza Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lonza Group's current EBITDA Margin % of 22.17% is 326.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lonza Group and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lonza Group's current EBITDA Margin % is 22.17%, which is 16% below median its own 10-year median of 26.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lonza Group stock overvalued right now?
Based on GuruFocus' analysis, Lonza Group (XSWX:LONN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF592.67, compared to a current price of CHF528.40 — trading 10.8% below its estimated fair value. The current EBITDA Margin % is 22.17%, which is 16% below median its 10-year median of 26.55 and 326.3% above the Medical Diagnostics & Research industry median of 5.20. Lonza Group's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Lonza Group (XSWX:LONN), the current EBITDA Margin % is 22.17% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lonza Group (XSWX:LONN) Overvalued in 2026?
Based on GuruFocus' analysis, Lonza Group stock appears to be undervalued.
The current stock price of CHF528.40 is trading 10.8% below its estimated GF Value™ of CHF592.67.
GuruFocus considers Lonza Group to be Modestly Undervalued.
Key valuation signals for XSWX:LONN:
EBITDA Margin %: 22.17% (16% below median its 10-year median of 26.55)
GF Value™: CHF592.67 vs. price of CHF528.40 (10.8% below fair value)
Industry Position: 326.3% above the Medical Diagnostics & Research median (#58 of 204)
No single metric tells the full story. See the XSWX:LONN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
82GF Score
Get the complete analysis for XSWX:LONN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LONN has been successfully added to your 
